Protalix BioTherapeutics (PLX) Stock Price, News & Analysis

Company Overview

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Key Stats

• Today's Range: $1.66 to $1.78
• 50-Day Range: $1.00 to $1.69
• 52-Week Range: $0.82 to $1.90
• Volume: 545,607 shs
• Average Volume: 346,059 shs
• Market Capitalization: $124.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PLX Stock Analysis - Frequently Asked Questions

How have PLX shares performed this year?

Protalix BioTherapeutics' stock was trading at $1.78 at the beginning of 2024. Since then, PLX shares have decreased by 4.8% and is now trading at $1.6950.
View the best growth stocks for 2024 here.

How were Protalix BioTherapeutics' earnings last quarter?

Protalix BioTherapeutics, Inc. (NYSE:PLX) released its earnings results on Wednesday, August, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.05. The business had revenue of $13.47 million for the quarter, compared to the consensus estimate of $12.50 million. Protalix BioTherapeutics had a negative trailing twelve-month return on equity of 30.89% and a negative net margin of 21.03%.

When did Protalix BioTherapeutics' stock split?

Protalix BioTherapeutics shares reverse split on the morning of Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Protalix BioTherapeutics' major shareholders?

Top institutional investors of Protalix BioTherapeutics include GSA Capital Partners LLP (0.59%), Point72 Asia Singapore Pte. Ltd. (0.06%), Jane Street Group LLC (0.06%) and Virtu Financial LLC (0.06%). Insiders that own company stock include Aharon Schwartz and Dror Bashan.
View institutional ownership trends.

How do I buy shares of Protalix BioTherapeutics?

Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Protalix BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Protalix BioTherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Walmart (WMT) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:PLX
• CUSIP: N/A
• CIK: 1006281
• Web: www.protalix.com
• Phone: 201-696-9345
• Fax: 972-4988-9489
• Employees: 200
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 84.75
• P/E Growth: N/A
• Net Income: $8.31 million
• Net Margins: -21.03%
• Pretax Margin: -72.93%
• Return on Equity: -30.89%
• Return on Assets: -11.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.98
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: $65.49 million
• Price / Sales: 1.91
• Cash Flow: $0.14 per share
• Price / Cash Flow: 11.94
• Book Value: $0.44 per share
• Price / Book: 3.85

Miscellaneous

• Outstanding Shares: 73,630,000
• Free Float: 68,995,000
• Market Cap: $124.80 million
• Optionable: Optionable
• Beta: 0.67